Personalis Q1 operating loss widens to $32.16 million; revenue drops 24.9% to $15.47 million

• Personalis posted Q1 revenue of USD 15.5 million, down 25% year over year, while net loss widened to USD 30 million from USD 15.75 million.
• Clinical test revenue rose to USD 1.4 million from USD 308,000, as clinical test volume tripled to 7,815 tests, up 26% sequentially.
• Pharma testing services revenue slipped to USD 10.72 million from USD 13.59 million, while enterprise sales fell to USD 393,000 from USD 2.47 million.
• Medicare coverage was secured for lung cancer surveillance in Stage I to III NSCLC, marking a second major coverage decision in six months alongside breast cancer.
• 2026 guidance was reaffirmed for revenue of USD 78 million to USD 80 million, clinical test volume of 43,000 to 45,000 tests, clinical revenue of USD 10 million to USD 11 million, and net loss of about USD 105 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Personalis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605071601BIZWIRE_USPR_____20260507_BW436129) on May 07, 2026, and is solely responsible for the information contained therein.